Evidence map›Paper›PMID 36366531›Full record

ArticleViruses2022

Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.

Yulia Ammour, Olga Susova, George Krasnov, Eugenia Nikolaeva, Vyacheslav Varachev, Yulia Schetinina, Marina Gavrilova, Alexey Mitrofanov, Anna Poletaeva, Ali Bekyashev and 4 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Yulia AmmourI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Olga SusovaN.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
George KrasnovEngelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0002-6493-8378
Eugenia NikolaevaI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Vyacheslav VarachevEngelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 119991 Moscow, Russia.
Yulia SchetininaI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Marina GavrilovaI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Alexey MitrofanovN.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
Anna PoletaevaN.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
Ali BekyashevN.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation, 115478 Moscow, Russia.
Evgeny FaizuloevI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Vitaly V ZverevI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Oxana A SvitichI.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.
Tatiana V NasedkinaEngelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 119991 Moscow, Russia.
Engelhardt Institute of Molecular Biology · RUMinistry of Health of the Russian Federation · RUResearch Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) accounts for almost half of all primary malignant brain tumors in adults and has a poor prognosis. Here we demonstrated the oncolytic potential of the L-16 vaccine strain of measles virus (MV) against primary human GBM cells and characterized the genetic patterns that determine the sensitivity of primary human GBM cells to oncolytic therapy. MV replicated in all GBM cells, and seven out of eight cell lines underwent complete or partial oncolysis. RNA-Seq analysis identified about 1200 differentially expressed genes (FDR < 0.05) with at least two-fold expression level change between MV-infected and uninfected cells. Among them, the most significant upregulation was observed for interferon response, apoptosis and cytokine signaling. One out of eight GBM cell lines was defective in type I interferon production and, thus, in the post-interferon response, other cells lacked expression of different cellular defense factors. Thus, none of the cell lines displayed induction of the total gene set necessary for effective inhibition of MV replication. In the resistant cells, we detected aberrant expression of metalloproteinase genes, particularly

Indexed as

GlioblastomaMeaslesOncolytic VirotherapyOncolytic VirusesVaccinesCell Line, TumorGene Expression ProfilingHumansInterferonsMeasles VaccineMeasles virusXenograft Model Antitumor AssaysInterferonsMeasles VaccineVaccinescancer immunotherapyglioblastoma multiformemeasles virusoncolytic viruses

Identifiers

PMID36366531
PMCPMC9696624
OpenAlexW4308955038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.